Vivus had an obesity drug that an FDA panel rejected. Upon further testing, review, and whatever else they do---a new FDA panel now recommends QNexAh for FDA approval. The dead can be resurrected. The price for shares of Vivus took off today on the news. I have no investment in either Vivus or NeurogesX.
Will Cue10Zah follow the rejuvenation track? Who knows? Many things are possible, including getting FDA approval eventually for NGSX for its hot chili pepper juice on a patch. All IMHO.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.